35L.F - Pherecydes Pharma Société anonyme
Chart Events
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 1.8750 |
| Open | 1.8950 |
| Bid | 1.8550 x N/A |
| Ask | 2.0100 x N/A |
| Day's Range | 1.8300 - 1.8950 |
| 52 Week Range | 1.7600 - 4.7050 |
| Volume | |
| Avg. Volume | 34 |
| Market Cap | 15.107M |
| Beta (5Y Monthly) | 0.88 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7400 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Related Research
Business WirePherecydes Announces That Legal Proceedings Have Been Initiated Against Erytech by Akkadian to Obtain the Postponement of the Vote on the Merger With Pherecydes
NANTES, France, June 05, 2023--Regulatory News: Pherecydes Pharma (FR0011651694 – ALPHE) (Paris:ALPHE), a biotechnology company specializing in extended phage therapy for treating antibiotic-resistant and/or complicated bacterial infections, announces that it has been informed that Akkadian Partners has initiated legal proceedings against Erytech to obtain the postponement of the vote at the Annual General Meeting on June 23 on the merger with Pherecydes. For further information, please refer to
Business WirePHERECYDES Announces the Availability of the Exemption Document Relating to the Proposed Combination With Erytech Pharma
NANTES, France, May 23, 2023--Regulatory News: PHERECYDES Pharma (FR0011651694 – ALPHE), a biotechnology company specializing in extended phage therapy for treating antibiotic-resistant and/or complicated bacterial infections, announces that it has published the exemption document relating to the proposed combination with Erytech Pharma (ISIN code: FR0011471135, ticker: ERYP).
Business WirePHERECYDES Strengthens its Corporate Links with ERYTECH to Prepare the Strategic Combination
NANTES, France, May 16, 2023--Regulatory News: PHERECYDES Pharma (FR0011651694 – ALPHE) (Paris:ALPHE), a biotechnology company specializing in extended phage therapy for treating antibiotic-resistant and/or complicated bacterial infections (the "Company"), announces progress on the strategic combination with ERYTECH and its implementation toward the merger.
Business WirePherecydes Pharma presented at the ECCMID congress an analytical performance protocol demonstrating the compliance of its Phagogram 1.5 with regulatory requirements
NANTES, France, April 17, 2023--Regulatory News: Pherecydes Pharma (FR0011651694 - ALPHE) (Paris:ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections (the "Company"), presented part of its analytical performance plan adapted to its Phagogram 1.5 on April 15, 2023, at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Copenhagen (Denmark).
Business WireTP ICAP Midcap Initiates Coverage of Pherecydes Pharma With a "Buy" Recommendation
NANTES, France, April 06, 2023--Regulatory News: Pherecydes Pharma (FR0011651694 - ALPHE) (Paris:ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections (the "Company"), today announced that TP ICAP Midcap, a brokerage firm and investment bank specializing in small and mid-caps, has initiated coverage of its shares.
Business WirePherecydes Pharma Announces Its 2022 Annual Financial Results and Specifies Its Development Plan For 2023
NANTES, France, March 30, 2023--Regulatory News: Pherecydes Pharma (FR0011651694 - ALPHE) (Paris:ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces its annual results for the year to December 31, 2022 and specifies its development prospects for 2023.
Business WirePherecydes Pharma Selected for the French Tech Health20 Program’s 2023 Class
NANTES, France, March 27, 2023--Regulatory News: Pherecydes Pharma (FR0011651694 – ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, announces that it has been selected for the 2023 French Tech Health20 program.
Business WirePherecydes Pharma Announces Its Participation in Several Scientific and Investor Conferences
NANTES, France, January 25, 2023--Regulatory News: Pherecydes Pharma (FR0011651694 - ALPHE) (Paris:ALPHE), a biotechnology company specializing in precision phage therapy for the treatment of resistant and/or complicated bacterial infections, announced today that its management team will participate in the following scientific and investor events:
Business WirePherecydes Pharma Announces its Financial Agenda for 2023
NANTES, France, January 03, 2023--Regulatory News: Pherecydes Pharma (FR0011651694 - ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announced its financial agenda for 2023.
Business WirePherecydes Pharma: Minutes of the Combined General Meeting of December 15, 2022
NANTES, France, December 15, 2022--Regulatory News: Pherecydes Pharma (FR0011651694 - ALPHE, eligible for PEA-PME equity savings plans) (Paris:ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces that the Combined General Meeting of December 15, 2022 was able to deliberate, the quorum having been reached.
Business WirePherecydes Pharma Announces the Positive Recommendation of the DSMB For the Continuation of Its Phase II Clinical Study PhagoDAIR in Osteoarticular Infections Caused by Staphylococcus aureus
NANTES, France, November 29, 2022--Regulatory News: Pherecydes Pharma (FR0011651694 - ALPHE, eligible for PEA-PME equity savings plans) (Paris:ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces that it has received a unanimous recommendation from the Data Safety Monitoring Board (DSMB) to continue without modification the phase II clinical study PhagoDAIR in osteoarticular infections of prostheses du
Business WirePherecydes Pharma Will Present Its Phagogram’s Latest Progress During an Oral Session at the Phage Futures US 2022 Conference
NANTES, France, November 16, 2022--Regulatory News: Pherecydes Pharma (FR0011651694 - ALPHE, eligible for PEA-PME equity savings plans) (Paris:ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces a presentation of its phagogram as an AST/IVD1 test during the Phage Futures US 2022 conference, which takes place in Boston, Massachusetts on November 16 and 17, 2022 and gathers the key players from the phag
Business WirePherecydes Pharma Publishes Its Half-Year 2022 Financial Results and Provides an Update on Its Development Plan
NANTES, France, October 27, 2022--Regulatory News: Pherecydes Pharma (FR0011651694 - ALPHE) (Paris:ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces its financial results for the first half of the year to June 30, 2022 and assesses its activities and development prospects.
Business WirePherecydes Pharma Announces Its Participation in a Number of Major Scientific and Investor Conferences
NANTES, France, September 27, 2022--Regulatory News: Pherecydes Pharma (FR0011651694 - ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces that its management team participated or will participate in the following scientific and investor events:
Business WirePherecydes Pharma Announces the Creation of an International Medical Advisory Board
NANTES, France, September 15, 2022--Regulatory News: Pherecydes Pharma (FR0011651694 - ALPHE) (Paris:ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces the setting up of a Medical Advisory Board comprising prominent international scientific and clinical experts in infectious diseases.
Business WirePherecydes Pharma Announces a First Registration of Its Phagogram as an in Vitro Diagnostic Test in Accordance With EC Directives
NANTES, France, September 12, 2022--Regulatory News: Pherecydes Pharma (FR0011651694 - ALPHE) (Paris:ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces the registration of its phagogram as an in vitro diagnostic test ("Phagogram 1.5") in accordance with Directive 98/79/EC.
Business WirePherecydes Pharma: Positive Preclinical Results for Inhaled Phage Therapy Presented to the Reanimation 2022 Conference
NANTES, France, June 27, 2022--Regulatory News: Pherecydes Pharma (Paris:ALPHE) (FR0011651694 – ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces that the results of a preclinical study undertaken with its phages have been presented at the Reanimation 2022 conference organized by the SRLF (Société de Réanimation de Langue Française, the French intensive care society) and held in Paris from June 22 t
Business WirePherecydes Pharma announces the enrollment of the first patient in the phase II study PhagoDAIR in the treatment of osteoarticular infections caused by Staphylococcus aureus
NANTES, France, June 15, 2022--Regulatory News: Pherecydes Pharma (FR0011651694 - ALPHE), a biotech company specializing in precision phage therapy for the treatment of resistant and/or complicated bacterial infections, announced today the enrollment of the 1st patient in the PhagoDAIR Phase II clinical trial.
Business WirePherecydes Pharma Organizes a Scientific Symposium During the 23rd National Days of Infectiology
PARIS, June 08, 2022--Regulatory News: Pherecydes Pharma (FR0011651694 - ALPHE, PEA-PME eligible), a biotech company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces it will participate to the scientific symposium "Phage therapy: French experience", which will be held on June 15, 2022 from 5:15 pm to 6:30 pm in the amphitheater A of the Palais des Congrès in Bordeaux, as part of the 23rd National Days of Infectiology (NDI).